Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression

Psychopharmacology(2021)10.1007/s00213-021-05762-6Source: DataRank Database

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression is a research paper published in Psychopharmacology (2021). On theSindex it has a DataRank of 1.5. It has been cited 53 times, with 43 citing works in its 1-hop citation network.

N/A

1.5DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access53 citations · 43 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT01179009

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 4.21)OA: hybridTopics (80)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (4)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 40%Citation Network 60%

Base Score Contribution

0.598

From this paper's citation signal

Citation Network Contribution

0.898

From 33 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 43 citers.

Symptom Management in Oncology: Depression and Anxiety
Seminars in Oncology Nursing20228 citations23 referencesContributes 0.096
Brain Features of Treatment-Resistant Depression
Psychiatric Clinics of North America202316 citations36 referencesContributes 0.079
Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
International Journal of Molecular Sciences202129 citations45 referencesContributes 0.076
Preliminary evidence that ketamine alters anterior cingulate resting-state functional connectivity in depressed individuals
Translational Psychiatry202326 citations44 referencesContributes 0.075
Neural connectivity moderators and mechanisms of ketamine treatment among treatment-resistant depressed patients: a randomized controlled trial
EBioMedicine202312 citations51 referencesContributes 0.050

Authors (10)

Ben Julian A. Palanca ORCID,Beau M. Ances ORCID,Evan D. Kharasch ORCID,Julia Schweiger ORCID,Michael Yingling ORCID

Live enrichment

PubMed:33483802 PMC:PMC7969576 OpenAlex:https://openalex.org/W3122632999

Washington University Institute for Clinical and Translational Research

Grant: UL1TR000448

National Center for Advancing Translational Sciences

Grant: UL1TR002345

National Institute of Mental Health

Grant: R25 MH11247

National Institutes of Health

Grant: R01MH118031

National Institutes of Health

Grant: R01NR015738

National Institutes of Health

Grant: R01AG057680

NIMH NIH HHS

Grant: F31 MH011247

NIDA NIH HHS

Grant: T32 DA007261

National Institutes of Health

Grant: 1R01NR015738-01A1

Exercise Training to Improve Brain Health in Older HIV+ Individuals

National Institutes of Health

Grant: 1UL1TR002345-01

Washington University Institute of Clinical and Translational Sciences

National Institutes of Health

Grant: 3R01MH118031-03S1

Functional Imaging Reserve in NeuroHIV (FIRN)

National Institutes of Health

Grant: 5R25MH112473-05

Washington University Psychiatry Residency Research Education Program

National Institutes of Health

Grant: 5P30NS098577-02

NINDS CENTER CORE FOR BRAIN IMAGING

National Institutes of Health

Grant: 1R01AG057680-01A1

FALLS: A MARKER OF PRECLINICAL ALZHEIMERS DISEASE

National Institutes of Health

Grant: 4UL1TR000448-10

Washington University Institute of Clinical and Translational Sciences

Sidney R. Baer, Jr. Foundation

Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis

FWCI

4.21

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.1007/s00213-021-05762-6.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00213-021-05762-6.pdf

publisherhttp://link.springer.com/content/pdf/10.1007/s00213-021-05762-6.pdf

publisherhttp://link.springer.com/article/10.1007/s00213-021-05762-6/fulltext.html

journalhttps://doi.org/10.1007/s00213-021-05762-6

Fields of Study

Functional Brain Connectivity StudiesTreatment of Major DepressionAdvanced MRI Techniques and Applications03 medical and health sciences0302 clinical medicineAdolescentAdultAgedAntidepressive AgentsClonidineDepressive Disorder, Treatment-ResistantFemaleGyrus CinguliHallucinogensHumansInfusions, IntravenousKetamineLimbic SystemMagnetic Resonance ImagingMaleMiddle AgedNerve NetPsychiatric Status Rating ScalesSympatholyticsTreatment OutcomeYoung Adult

MeSH Terms

AdolescentAdultAgedAntidepressive AgentsClonidineFemaleGyrus CinguliHallucinogensHumansInfusions, IntravenousKetamineLimbic SystemMagnetic Resonance ImagingMaleMiddle AgedNerve NetPsychiatric Status Rating ScalesSympatholyticsTreatment OutcomeYoung AdultDepressive Disorder, Treatment-Resistant

Keywords

Treatment-resistant depressionKetamineDepression (economics)MedicinePsychologyNeurosciencePharmacologyAntidepressantAnesthesiaHippocampusLimbic systemDepressionFunctional ConnectivitySubgenual Anterior Cingulate CortexAdultMaleAdolescentGyrus CinguliClonidineDepressive Disorder, Treatment-ResistantHumansInfusions, IntravenousOriginal InvestigationAgedPsychiatric Status Rating ScalesMiddle AgedMagnetic Resonance ImagingAntidepressive AgentsTreatment OutcomeHallucinogensSympatholyticsFemaleNerve Net

Sustainable Development Goals

SDG 3: 3. Good healthSDG 12: 12. Responsible consumptionSDG 16: 16. Peace & justiceSDG 0: Good health and well-being